BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38498243)

  • 1. Associations of circulating advanced glycation end products and their soluble receptors with cancer risk: A systematic review and meta-analysis of observational studies.
    Hajizadeh-Sharafabad F; Shojaei-Zarghani S; Sharifi-Zahabi E; Gerami F; Pashaei MR
    Glycoconj J; 2024 Feb; 41(1):35-46. PubMed ID: 38498243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Advanced Glycation End Products and Their Soluble Receptors in Relation to All-Cause and Cardiovascular Mortality: A Systematic Review and Meta-analysis of Prospective Observational Studies.
    Sharifi-Zahabi E; Sharafabad FH; Abdollahzad H; Malekahmadi M; Rad NB
    Adv Nutr; 2021 Dec; 12(6):2157-2171. PubMed ID: 34139010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary protein intake and circulating advanced glycation end product/receptor for advanced glycation end product concentrations in the Health, Aging, and Body Composition Study.
    Brinkley TE; Semba RD; Kritchevsky SB; Houston DK;
    Am J Clin Nutr; 2020 Dec; 112(6):1558-1565. PubMed ID: 33301008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals.
    Scavello F; Tedesco CC; Castiglione S; Maciag A; Sangalli E; Veglia F; Spinetti G; Puca AA; Raucci A
    Biomark Med; 2021 Aug; 15(11):785-796. PubMed ID: 34236256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble receptor for advanced glycation end products (sRAGE) is associated with obesity rates: a systematic review and meta-analysis of cross-sectional study.
    Tayyib NA; Ramaiah P; Alshahrani SH; Margiana R; Almalki SG; Kareem AK; Zabibah RS; Shbeer AM; Ali SHJ; Mustafa YF
    BMC Endocr Disord; 2023 Dec; 23(1):275. PubMed ID: 38102636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Fat Content and Liver Enzymes Are Associated with Circulating Free and Protein-Bound Advanced Glycation End Products, Which Are Associated with Low-Grade Inflammation: The CODAM Study.
    Bijnen M; van Greevenbroek MMJ; van der Kallen CJH; Scheijen JL; van de Waarenburg MPH; Stehouwer CDA; Wouters K; Schalkwijk CG
    J Diabetes Res; 2019; 2019():6289831. PubMed ID: 31218233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer.
    Jiao L; Taylor PR; Weinstein SJ; Graubard BI; Virtamo J; Albanes D; Stolzenberg-Solomon RZ
    Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1430-8. PubMed ID: 21527578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
    Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
    Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
    Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
    Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Advanced Glycation End Products, Soluble RAGE Receptor, and Endothelium Dysfunction, Evaluated by Circulating Endothelial Cells and Endothelial Progenitor Cells in Patients with Mild and Resistant Hypertension.
    Gryszczyńska B; Budzyń M; Begier-Krasińska B; Osińska A; Boruczkowski M; Kaczmarek M; Bukowska A; Iskra M; Kasprzak MP
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.
    Sabbatinelli J; Castiglione S; Macrì F; Giuliani A; Ramini D; Vinci MC; Tortato E; Bonfigli AR; Olivieri F; Raucci A
    Cardiovasc Diabetol; 2022 Jun; 21(1):95. PubMed ID: 35668468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of plasma advanced glycation end-products and their soluble receptor with type 2 diabetes among Chinese adults.
    Chen L; Wang Q; Lv Y; Xu W; Jiang G; Li Y; Luo P; He R; Liu L
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3735. PubMed ID: 37817474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
    Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
    Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodialysis Patients with Higher Serum Levels of Soluble Receptor for Advanced Glycation End Products Have an Increased Risk for Arteriovenous Fistula Failure.
    Ticala M; Rusu CC; Moldovan D; Potra AR; Tirinescu DC; Coman AL; Bondor CI; Budisan L; Kacsó IM
    Blood Purif; 2022; 51(9):764-771. PubMed ID: 34794141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
    Melin EO; Dereke J; Hillman M
    Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of advanced glycation end products (AGEs) are increased and their soluble receptor (sRAGE) reduced in Hashimoto's thyroiditis.
    Ruggeri RM; Barbalace MC; Cristani MT; Alibrandi A; Giovinazzo S; Giuffrida G; Trimarchi F; Cannavò S; Campennì A
    J Endocrinol Invest; 2020 Sep; 43(9):1337-1342. PubMed ID: 32232775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The different roles for the advanced glycation end products axis in heart failure and acute coronary syndrome settings.
    Paradela-Dobarro B; Agra RM; Álvarez L; Varela-Román A; García-Acuña JM; González-Juanatey JR; Álvarez E; García-Seara FJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1050-1060. PubMed ID: 31371263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can advanced glycation end-products and their receptors be affected by weight loss? A systematic review.
    Tavares JF; Ribeiro PVM; Coelho OGL; Silva LED; Alfenas RCG
    Obes Rev; 2020 Jun; 21(6):e13000. PubMed ID: 31950676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble receptor for advanced glycation end products and risk of liver cancer.
    Moy KA; Jiao L; Freedman ND; Weinstein SJ; Sinha R; Virtamo J; Albanes D; Stolzenberg-Solomon RZ
    Hepatology; 2013 Jun; 57(6):2338-45. PubMed ID: 23325627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
    Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.